Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals Inc (NQ: RYTM )

13.70 USD +0.71 (+5.43%)
Streaming Delayed Price Updated: 11:37 AM EDT, Sep 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 57,082
Open 13.25
Bid (Size) 13.67 (2)
Ask (Size) 13.72 (2)
Prev. Close 12.99
Today's Range 13.01 - 13.95
52wk Range 11.53 - 43.26
Shares Outstanding 50,227,489
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting
From GlobeNewswire News Releases
Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain
From GlobeNewswire News Releases

Performance

YTD
-54.89%
-54.89%
1 Month
+5.59%
+5.59%
3 Month
-33.62%
-33.62%
6 Month
-32.37%
-32.37%
1 Year
-38.89%
-38.89%

More News

Read More
Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger i
From GlobeNewswire News Releases
Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome
From GlobeNewswire News Releases
Rhythm Pharmaceuticals Announces CMO Transition
From GlobeNewswire News Releases
Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference
From GlobeNewswire News Releases
Rhythm Pharmaceuticals to Present at the 59th Annual ESPE Meeting
From GlobeNewswire News Releases
Rhythm Pharma's Imcivree Wins UK Approval For Obesity, Hunger Control
Tags FDA Health Care Biotech
From Benzinga
Analysts Anticipate IWV Will Reach $291
Tags ETFs
From ETF Channel
Commit To Buy Rhythm Pharmaceuticals At $7.50, Earn 14.2% Annualized Using Options
Tags Stocks
From Market News Video
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Tags TMO CRDL TTOO
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.